The evolving therapeutic revolution in adult acute lymphoblastic leukemia
Cancer · 2025
DOI: 10.1002/cncr.35872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Hagop Kantarjian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute/National Institutes of Health, Charif Souki Cancer Research Fund.
Abstract (Originalsprache)
The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia‐like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions, like the BCR::ABL1 tyrosine kinase inhibitors, as well as novel agents that target CD19 and CD22: the CD22 antibody–drug conjugate inotuzumab ozogamicin, the bispecific CD3/CD19 T‐cell engager antibody blinatumomab, and CD19 chimeric antigen receptor T‐cell therapies. These combinations have improved the long‐term survival rates in B‐cell ALL to 70%, and in Philadelphia chromosome‐positive ALL to 80%–90%. The desired goals are to achieve cure rates comparable to those in pediatric ALL and to reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Clinical Hematology Department and Stem Cell Transplantation Unit, Catalan Institute of Oncology, Barcelona, Spain.
ORCID-Profile: Hagop Kantarjian, Cristina Papayannidis, Josep-Maria Ribera, Nicholas J Short, Helen T Chifotides, Elias Jabbour
Förderung
- NCI NIH HHS
- National Cancer Institute/National Institutes of Health
- Charif Souki Cancer Research Fund
- National Cancer Institute
Zitieren
APA
Kantarjian, H., Jain, N., Litzow, M. R., Luger, S. M., Papayannidis, C., Ribera, J. M., Short, N. J., Chifotides, H. T., & Jabbour, E. (2025). The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.35872
Vancouver
Kantarjian H, Jain N, Litzow MR, Luger SM, Papayannidis C, Ribera JM, et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer. 2025. doi:10.1002/cncr.35872
BibTeX
@article{Kantarjian2025,
author = {Kantarjian, Hagop and Jain, Nitin and Litzow, Mark R and Luger, Selina M and Papayannidis, Cristina and Ribera, Josep-Maria and Short, Nicholas J and Chifotides, Helen T and Jabbour, Elias},
title = {The evolving therapeutic revolution in adult acute lymphoblastic leukemia},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35872}
}
EUVIMED